DR 5001Alternative Names: Adenovirus vaccine - Barr Laboratories; DR-5001
Latest Information Update: 14 Jun 2010
At a glance
- Originator Barr Laboratories
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Adenovirus infections
Most Recent Events
- 11 Dec 2008 Preregistration for Adenovirus infections in USA (PO)
- 19 May 2008 Phase III development is ongoing
- 30 Sep 2006 Phase-III clinical trials in Adenovirus infections in USA (PO)